Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Inclusion Criteria: * Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy Exclusion Criteria: * LDL-C levels \> 250 mg/dL (6.48 mmol/L) * Triglycerides levels \> 350mg/dL (3.95 mmol/L) * Conditions / situations such as: * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels * Active liver disease * High estimated risk of Coronary Heart Disease * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive * Pregnant or breast-feeding women, * Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.